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Estradiol suppresses type I collagen synthesis in mesangial cells female gender on the progression of atherosclerosis is
via activation of activator protein-1. thought to reflect, in part, reduced accumulation of vas-
Background. Estradiol suppresses the synthesis of type I cular wall extracellular matrix [1]. Consistent with thiscollagen by murine mesangial cells. However, neither the a1(I)
view are observations that estrogen administration re-nor the a2(I) collagen gene contains an estrogen-response ele-
duces collagen deposition in the aorta of hypertensivement. Because estradiol modulates the transcription of several
genes that lack an estrogen-response element but contain a regu- and hypercholesterolemic animals in vivo and reduces
latory activator protein-1 (AP-1) binding motif, we hypothe- type I and type III collagen synthesis by vascular smooth
sized that AP-1 may mediate estradiol-induced suppression of muscle cells in vitro [1]. By way of analogy with athero-type I collagen synthesis.
sclerosis, the accumulation of glomerular extracellularMethods. We measured type I collagen synthesis in murine
mesangial cells exposed to estradiol, phorbol 12-myristate 13- matrix after renal injury is a precursor to the develop-
acetate (an activator of AP-1), or curcumin (an inhibitor of ment of glomerular obsolescence and progressive loss of
AP-1). We also assessed the effects of estradiol on the steady- renal function. The ability of estradiol to suppress collagen
state level of c-fos and c-jun mRNA and on the binding of
synthesis by glomerular mesangial cells may translate intomesangial cell nuclear extracts to an AP-1 consensus binding
reduced accumulation of collagen and thereby limit thesite oligonucleotide.
Results. Estradiol (10210 m to 1027 m) suppressed type I colla- development of glomerulosclerosis [1–5].
gen synthesis by murine mesangial cells in a dose-dependent Although the genes for the a1 and a2 chains of type I
manner (1027 m, 43.7 6 8.2% of control values, P , 0.001). collagen are located on different chromosomes, transcrip-Phorbol 12-myristate 13-acetate (10 mm, four-hr exposure) also
tion of these genes is under coordinate control [6, 7].decreased type I collagen in the media. In contrast, curcumin
We have previously shown that estradiol suppresses mes-(1 mm) increased type I collagen. Estradiol increased the steady-
state level of c-fos mRNA twofold at 30 minutes, with a return angial cell synthesis of type I collagen and reduces the
to basal levels at one hour. This was associated with a greater steady-state level of mRNA for the a2 chain [2]. How-than threefold increase in the binding of nuclear extracts from
ever, the genes encoding the a1 and a2 chains of typeestradiol-treated mesangial cells to an AP-1 consensus binding
I collagen do not contain estrogen-response elementssite oligonucleotide. Estradiol-enhanced binding of nuclear ex-
tracts to the AP-1 oligonucleotide was reversed by cyclohexi- (ERE) [8]. Estradiol has been shown to regulate the
mide. transcription of many genes that lack an ERE but contain
Conclusions. These data suggest that estradiol suppresses an activator protein-1 (AP-1) binding site [9, 10]. Incollagen I synthesis by murine mesangial cells via enhanced
this context, both of the a1(I) and a2(I) collagen geneAP-1 activity.
promoters contain consensus AP-1 binding sites [11–14].
In addition, the first intron of the a1(I) collagen geneObservations in experimental animals and in humans
contains a nonconsensus AP-1 binding site [8, 15–17].
show that the rate of progression of renal disease is
These motifs have been shown to regulate type I collageninfluenced by gender [1]. The protection afforded by
gene transcription [15–17]. We postulated that interac-
tions between estradiol and the transcription factor AP-1
1 See Editorial, p. 1577. mediate the inhibitory effect of estradiol on type I colla-
gen synthesis. Estradiol might influence AP-1–regulatedKey words: mesangial matrix, transcription factors, gender hormones,
activator protein-1, progressive renal disease. gene expression by increasing the transcription of c-fos
or c-jun, by competing for essential cofactors requiredReceived for publication March 26, 1998
for AP-1–mediated gene transcription (cAMP-respon-and in revised form November 12, 1998
Accepted for publication November 12, 1998 sive element binding protein/p300) or by altering the
binding of AP-1 to its DNA recognition site via protein– 1999 by the International Society of Nephrology
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protein interactions [18–20]. In this study, we show that transferred to a polyvinylidene difluoride microporous
membrane.estradiol suppresses type I collagen synthesis by enhanc-
After blotting, the membrane was immediately placeding AP-1 activity.
into blocking buffer [2% bovine serum albumin in wash
buffer (10 mm Tris, 100 mm NaCl, 0.1% Tween 20, dis-
METHODS tilled H2O added to 1 liter)] on a shaking apparatus for
Isolation and characterization of murine mesangial cells 30 minutes at 378C. The blocking buffer was discarded
and replaced with new blocking buffer containing goatMesangial cells were isolated from kidneys of 8- to 10-
antibovine type I collagen antibody (1:250 dilution;week-old naive male SJL/J (H-2S) mice by differential
Southern Biotechnology Assoc., Birmingham, AL, USA).glomerular sieving [21]. Studies were performed on an
The membrane was incubated with the primary antibodyimmortalized, differentiated murine mesangial cell line
solution on a shaking apparatus for 30 minutes at 378C.that we transformed with nonreplicating, noncapsid-
The membrane was next washed for 30 minutes withforming SV40 virus (strain Rh 911). The cells express
agitation. The membrane was then placed in 5% nonfatreceptors for angiotensin II and stain positively for Thy-1
milk in wash buffer containing rabbit antigoat IgG conju-antigen, desmin, vimentin, and types I and IV collagen,
gated to horseradish peroxidase (Sigma). The antibodybut fail to bind antibody directed against a proximal
conjugate was allowed to incubate for 30 minutes at 378Ctubular antigen [22]. Where indicated, replicate studies
with agitation. After washing, the membrane was treatedwere performed with nontransformed mesangial cells,
with enhanced chemiluminescence reagent (Amershampassages 5 through 7. Cells were grown in RPMI media
Life Science, Arlington Heights, IL, USA) according to(GIBCO Laboratories, Grand Island, NY, USA) con-
the instructions of the manufacturer. Kodak X-OMATtaining 10% fetal calf serum (FCS; Gibco) and 1% peni-
4R film was exposed to the blot for 10 minutes. The bandscillin/streptomycin (Sigma Chemical Co., St. Louis, MO,
were quantitated by laser densitometry. We determinedUSA).
that the amount of protein loaded into each lane was
within the linear range of detection of type I collagenWestern blotting for type I collagen
by Western blotting in our system (data not shown).Mesangial cells were plated on 6-well plates (Becton
Human type I collagen (Sigma) was used as a positive
Dickenson, Franklin Lakes, NJ, USA) and were grown
control in Western blotting experiments. The antitype I
in phenol red-free Dulbecco’s modified Eagle’s media
collagen antibody did not significantly cross-react with
(DMEM) supplemented with 10% FCS (Gibco). The type IV collagen (Sigma). Appropriate negative controls
final estradiol concentration in the media was less than using irrelevant antibodies were also performed.
10211 m (manufacturer’s specifications). Cells were ex- Studies were performed in the presence and absence
posed to phorbol 12-myristate 13-acetate (PMA; 10 mm), of a metalloproteinase inhibitor (10 mm of 1,10-phenan-
curcumin (1 mm), 17b-estradiol (10210 m to 1027 m), 17a- troline) and a commercial protease-inhibitor cocktail-
estradiol (1027 m), cycloheximide (10 mg/ml; Sigma), ICI containing serine, cysteine, and aspartic protease inhibi-
182,780 (1027 m or 1026 m; Tocris Cookson, St. Louis, MO, tors and an aminopeptidase inhibitor (Sigma). Results
USA), or control media for the indicated time periods in obtained in the presence and absence of the protease
the presence of ascorbic acid (50 mg/ml) and b-amino- inhibitor cocktail were identical and have been combined.
propionitrile (80 mg/ml) (Sigma). Media were collected
and concentrated using an Amicon Centriprep-10 con- Preparation of nuclear extracts
centrator (Grace and Co., Beverly, MA, USA). Protein Mesangial cells were scraped into phosphate-buffered
content was measured in a 0.1 ml aliquot (Bio-Rad Pro- saline (PBS) and were pelleted by centrifuging at 3000 3 g
tein Assay, Richmond, CA, USA). To prepare the sam- for 10 minutes at 48C [23]. The cells were resuspended
ples for sodium dodecyl sulfate-polyacrylamide gel elec- in hypotonic buffer [10 mm N-2-hydroxyethylpiperazine-
trophoresis (SDS-PAGE), 1 ml of 10% trichloroacetic N9-2-ethanesulfonic acid (HEPES), pH 7.9, 1.5 mm
acid was added to 4 mg protein of concentrated media, MgCl2, 10 mm KCl, 0.2 mm phenylmethylsulfonyl fluoride
and the final volume was brought to 2 ml with distilled (PMSF), 0.5 mm dithiothreitol (DTT)], recentrifuged at
water. The sample was vortexed and then centrifuged at 3000 3 g for five minutes, resuspended in the hypotonic
2000 r.p.m. for 10 minutes. The pellet was dissolved in buffer, and allowed to swell for 10 minutes on ice. The
1 ml of loading buffer (2% SDS, 10% glycerol, 50 nm cells were homogenized in a glass Dounce homogenizer.
Tris, 3% bromophenol blue, 2% b mercaptoethanol, pH Nuclei were collected by centrifuging at 3300 3 g for 15
7.6; all reagents were from Sigma), boiled for five min- minutes. The nuclear pellet was resuspended in low-salt
utes, then immediately placed on ice. Fifty micrograms buffer [20 mm HEPES, 2% glycerol, 1.5 mm MgCl2, 0.02 m
of sample were loaded in each well. SDS-PAGE was KCl, 0.2 mm ethylenediaminetetraacetic acid (EDTA),
0.2 mm PMSF, 0.5 mm DTT]. While stirring gently, aperformed by standard techniques, and proteins were
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volume of high-salt buffer (1.2 m KCl) equal to one half test for independent variables. Statistical significance was
defined using an overall type I error of 0.05.of the packed nuclear volume was added in a dropwise
fashion. The protein concentration was measured by col-
orimetric assay (Bio-Rad).
RESULTS
Western blottingElectrophoretic mobility shift assay
Four micrograms of nuclear extracts were mixed with 17b-Estradiol (10210 m to 1027 m) decreased type I
collagen in the media in a dose-dependent manner. A2 mg of poly (dI:dC) in 20 ml of a reaction buffer con-
sisting of 25 mm HEPES, pH 7.5, 1.2 mm dithiothreitol, statistically significant effect was achieved at an estradiol
concentration of 5 3 1029 m (77.2 6 4.3%, expressed as4 mm MgCl2, 150 mm NaCl, 5% glycerol, 0.005% brom-
phenol blue, and 0.05% Nonidet P-40 [23]. The mix- a percentage of untreated, control cells, P , 0.034 vs.
control, N 5 10; Fig. 1). Replicate studies performed inture was incubated on ice for 15 minutes, followed by
an addition of 10 fmol of 32P end-labeled AP-1 con- transformed and nontransformed cells yielded identical
results (N 5 2). ICI 182,780, a high-affinity estrogen recep-sensus binding sequence oligonucleotide (nucleotide se-
quence, 59-CGCTTGATGAGTCAGCCGGAA-39; Pro- tor antagonist, reversed the suppressive effect of 17b-
estradiol (1027 m and 1028 m) on collagen I synthesismega, Madison, WI, USA). Incubation was continued
for 30 minutes. The incubation mixture was subjected [estradiol (1028 m) 1 ICI 182,780 (1027 m), 102.7 6 1.8,
P 5 NS vs. control, P , 0.001 vs. estradiol (1028 m),to electrophoresis on a 6% polyacrylamide gel in Tris-
glycine buffer. The gels were dried, and autoradiography N 5 3]. 17a-Estradiol (1027 m), a time-dependent mixed
agonist/antagonist of 17b-estradiol, had no effect on col-was performed at 2708C with an intensifying screen.
Bands were quantitated by laser densitometry (model lagen I in the media (94.6 6 2.9, P 5 NS vs. control,
N 5 3). Because the most striking effects on collagen I300S; Molecular Dynamics, Sunnyvale, CA, USA). Com-
petition experiments were performed with a 200-fold synthesis were observed with an estradiol concentration
of 1027 m (54.7 6 2.9, P , 0.001 vs. control), this concen-excess of unlabeled AP-1 consensus binding sequence
oligonucleotide. Supershift assays were performed by tration was used in subsequent experiments.
Phorbol 12-myristate 13-acetate (PMA; 10 mm, 4-hrpreincubating nuclear extracts with c-Jun antibody (On-
cogene Research Products, Cambridge, MA, USA) for exposure) decreased type I collagen in the media (54.0 6
10.6, P , 0.001 vs. control, N 5 10; Fig. 2). In contrast,30 minutes prior to the binding reaction.
curcumin (1 mm) increased type I collagen in the media
Northern blot analysis (180.0 6 22.5, P , 0.002 vs. control, N 5 10). Replicate
studies performed in transformed and nontransformedThe steady-state messages for c-fos and c-jun were
determined by Northern blot analysis. Mesangial cells cells yielded identical results (N 5 2).
were exposed to control media or the indicated agents
Northern blotting for c-fos and c-junfor 24 hours. After extraction of total RNA [24], 10 mg
aliquots of the extract were run on a 1% agarose gel Exposure of mesangial cells to estradiol for 30 minutes
increased the steady-state message for c-fos in a dose-and transferred to nylon filters [25]. Labeling of the
cDNA probe was accomplished by random-prime tran- dependent manner (1027 m estradiol, 200.7 6 18.0%,
expressed as a percentage of values obtained in un-scription using 32P-dCTP [26]. Nylon filters were prehy-
bridized (658C, 3 hr) in a solution containing 1 m NaCl treated, control cells and normalized for GAPDH, P ,
0.001 vs. control, N 5 3; 1028 m estradiol, 155.7 6 9.0%,and 1% SDS and then hybridized with the labeled cDNA
probe for 16 hours [25, 26]. After the filters were washed P , 0.05 vs. control, N 5 3; Fig. 3). Steady-state levels
of mRNA for c-fos returned to baseline values by oneto high stringency, autoradiography with intensifying
screens was performed at 2708C. Hybridization of the hour (1027 m estradiol, 104.2 6 8.3, P 5 NS vs. control).
In contrast, the steady-state message for c-jun was notspecific mRNAs was quantitated by laser densitometry.
Hybridization for glyceraldehyde-3-phosphate dehydro- affected by estradiol treatment (N 5 3; Fig. 3).
genase (GAPDH) was used to normalize for any differ-
Gel shift assayences in RNA loading. The cDNA probes for c-Fos,
c-Jun, and GAPDH were obtained from a commercial Corresponding to the ability of estradiol to increase
steady-state levels of c-Fos mRNA, nuclear extracts fromsource (Oncogene).
mesangial cells treated with estradiol showed increased
Statistics binding to an AP-1 consensus binding sequence oligonu-
cleotide. Increased binding was observed in nuclear ex-For each experiment, the mean of replicate determina-
tions was calculated. The data are means 6 se. Compari- tracts from cells exposed to estradiol for four hours
(332.4 6 29.6% of values obtained with untreated, con-sons among groups were performed with analysis of vari-
ance with Scheffe’s correction or Student’s two-tailed t- trol nuclear extracts, P , 0.001 vs. time 0, N 5 6; Fig.
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Fig. 1. (Top) Western blotting for type I col-
lagen in the media of mesangial cells exposed
to estradiol (10210 M to 1027 M) for 24 hours
in the presence of a protease inhibitor cocktail.
The first lane is a positive control. (Bottom)
Densitometry readings from Western blots
measuring type I collagen in the media of mes-
angial cells exposed to the indicated concen-
trations of estradiol for 24 hours. Abbrevia-
tions are: Con, control (estradiol omitted); E2,
17b-estradiol; m, molar. *P , 0.001 vs. Con;
**P , 0.004 vs. Con; DP , 0.034 vs. Con.
(supershift). Replicate studies performed in transform-
ed and nontransformed cells yielded identical results
(N 5 2).
Cycloheximide (10 mg/ml, pretreatment for 4 hr) re-
duced the binding of nuclear extracts from cells treated
with estradiol for four hours to the consensus sequence
AP-1 binding oligonucleotide (256.7 6 27.8 vs. 137.3 6
36.2, P , 0.001, N 5 4; Fig. 5). In contrast, cycloheximide
alone caused an inconsistent increase in binding. Repli-
cate studies performed in transformed and nontrans-
formed cells yielded identical results (N 5 2).
Binding to the consensus sequence AP-1 oligonucleo-
tide by nuclear extracts from cells exposed to both estra-
diol and curcumin (1 mm) did not differ from results
obtained with control cells (98.8 6 10.2, P 5 NS vs. con-
trol, P , 0.035 vs. estradiol, N 5 4; Fig. 6). Nuclear extracts
from mesangial cells treated with PMA (10 mm, 4 hr)
Fig. 2. (Top) Western blotting for type I collagen in the media of also showed increased binding to the AP-1 binding oligo-
mesangial cells exposed to control media, estradiol (1027 M), curcumin nucleotide (228.3 6 28.4, P , 0.02 vs. control, N 5 4;(1 mM), or phorbol 12-myristate 13-acetate (PMA; 10 mM). (Bottom)
Fig. 6). Binding of nuclear extracts from cells exposedDensitometry readings from Western blots measuring the effects of the
indicated agents on mesangial cell type I collagen synthesis. Abbrevia- to both PMA and curcumin (1 mm) did not differ from
tions are: Con, control; Estr, estradiol; Cur, curcumin; PMA, phorbol results obtained with control cells (128.0 6 17.7, P 512-myristate 13-acetate. *P , 0.016 vs. Con; **P , 0.002 vs. Con;
NS vs. control, P , 0.03 vs. PMA). The tendency for***P , 0.001 vs. Con.
curcumin alone to reduce binding to the TRE did not
achieve statistical significance (72.6 6 13.6, P , NS
vs. control). Replicate studies performed in transform-
4). In competition experiments, a 200-fold excess of unla- ed and nontransformed cells yielded identical results
beled AP-1 consensus binding sequence oligonucleotide (N 5 2).
markedly suppressed the binding of nuclear extracts
from cells treated with estradiol for four hours (Fig. 4).
DISCUSSIONPreincubation of nuclear extracts treated with estradiol
for four hours with anti-Jun antibody markedly reduced Attention has recently focused on “cross-talk” be-
tween estrogen receptors and members of the AP-1 fam-the intensity of binding (Fig. 4). However, we were un-
able to detect a decrease in the mobility of the complex ily of transcription factors [18–20]. The AP-1 family
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Fig. 4. (Top) The binding of nuclear extracts from mesangial cells
exposed to estradiol (1027 M) for the indicated time period to a consensus
binding sequence activator protein-1 (AP-1) oligonucleotide. Lane 1,
control; lane 2, nuclear extracts omitted; lane 3, excess cold AP-1 oligo-
nucleotide; lane 4, estradiol (0.5 hr); lane 5, estradiol (4 hr); lane 6,
Fig. 3. (Top) Northern blotting for c-fos, c-jun, and GAPDH in mesan- estradiol (24 hr); lane 7, estradiol (48 hr); lane 8, estradiol (4 hr);
gial cells exposed to estradiol (1027 M) for the indicated time period. lane 9, estradiol (4 hr) preincubated with anti-Jun antibody. (Bottom)
(Bottom) Steady-state level of c-fos mRNA (normalized for GAPDH) Densitometry readings from gel shift studies measuring specific binding
in mesangial cells exposed to estradiol (1027 m) for the indicated time of nuclear extracts from mesangial cells exposed to estradiol (1027 m)
period, expressed as a percentage of values obtained in untreated, for the indicated time period to a consensus binding sequence AP-1
control cells. *P , 0.001 vs. baseline value. oligonucleotide. Specific binding is reflected in the uppermost band.
Abbreviations are: 2NE, nuclear extracts omitted; Comp, competition
study. *P , 0.001 vs. Con.
includes the protein products of the c-fos and c-jun proto-
oncogenes (c-Fos and c-Jun), which form complexes that anterior pituitary gland, and human osteoblast-like cells
bind to AP-1–response elements on DNA [27]. Several [10]. The proto-oncogene c-jun also contains a noncon-
models have emerged to explain the cross-talk between sensus estrogen-responsive enhancer [30]. Estradiol in-
these two families of transcription factors, including co- creases the transcription of c-jun in rat uterine and myo-
occupancy at composite response elements, tethering, metrial tissue and in avian liver [10]. In contrast, estradiol
mutual transcription inhibition, and competition for lim- does not affect or actually suppress proto-oncogene tran-
iting quantities of coactivator proteins (cAMP-respon- scription in other tissues [10]. Tissue-specific differences
sive element binding protein/p300) [18–20]. However, in the effects of estradiol on proto-oncogene expression
the sequences flanking the AP-1 binding site must be may reflect requirements for tissue-specific transcription
important in determining estrogen/AP-1 interactions be- cofactors.
cause not all genes containing an AP-1 binding motif in Estradiol can stimulate the transcription of genes that
their regulatory regions are estrogen responsive. contain AP-1–binding motifs but lack an ERE via estra-
One mechanism whereby estrogen receptors can inter- diol-stimulated transcription of c-fos and c-jun, which
act with AP-1 is via enhanced transcription of c-fos or in turn mediates gene activation [9, 10]. For example,
c-jun. The murine c-fos proto-oncogene contains an im- estradiol enhances transcription of the myometrial gap
perfect palindromic ERE in its 59 flanking region and junction protein connexon-43, which lacks an ERE, by
another nonconsensus ERE in its 39 flanking region, enhancing the expression of c-Fos and c-Jun at a tran-
which bind estrogen receptor complexes [28, 29]. Estra- scriptional level [9]. This results in increased binding of
diol rapidly increases the expression of c-fos mRNA in AP-1 to an AP-1–responsive element in the connexon
rat and human endometrial cells, human breast cancer promoter to active gene transcription [9].
The first intron of the human a1(I) collagen gene con-cells, rat uterus, rat vascular smooth muscle cells, rat
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vation that phorbol esters increase transcription of a trans-
fected promoter construct containing this AP-1 binding
site but reduce transcription of the endogenous gene [32].
It was suggested that the phorbol ester-responsive sup-
pressor element in the endogenous a2(I) collagen gene
is located outside of the promoter region studied [32].
Phorbol ester-responsive genes share a consensus mo-
tif (phorbol ester responsive element) that is recognized
by AP-1 [33]. Phorbol esters (such as PMA) activate
AP-1 at both post-translational and transcriptional levels
[27, 34, 35]. Curcumin (diferuloylmethane) is a well-
characterized inhibitor of AP-1 activity. Curcumin re-
verses phorbol ester-induced post-translational modi-
fication of c-Jun and reverses enhanced c-jun gene
transcription [34]. Although transcription of the c-fos
gene is not affected by curcumin, curcumin reverses
phorbol ester-induced increases in nuclear c-Fos protein
by inducing a hyperphosphorylated form of c-Fos that
is susceptible to degradation [34, 35].
We examined the effects of PMA on collagen synthesis
after only four hours of exposure to avoid phorbol ester-
induced down-regulation of protein kinase C, which may
be observed after longer periods of exposure [36]. Thus,
our experimental results reflect PMA-induced up-regu-
lation of protein kinase C and AP-1 activity. Phorbol
esters have been shown to suppress type I collagen syn-Fig. 5. (Top) Effect of pretreatment with cycloheximide (10 mg/ml, 4
hr) on estradiol- stimulated binding of nuclear extracts to a consensus thesis [37–42], reduce a1(I) collagen gene transcription,
binding sequence AP-1 oligonucleotide. Cells were treated with estra- reduce the steady-state level of a1(I) collagen mRNAdiol (1027 m) for four hours. (Bottom) Densitometry readings from gel
[37–39, 41, 43, 44], or reduce the steady-state level ofshift studies measuring the effect of cycloheximide (10 mg/ml, 4 hr) on
estradiol-stimulated binding of nuclear extracts to a consensus binding a2(I) collagen mRNA in a variety of fibroblast, epidermal
sequence AP oligonucleotide. Cells were treated with estradiol (1027 m) cell, and osteoblast cell lines [32, 38, 41, 44, 45]. Phorbol
for four hours. Abbreviations are: Con, control; 2NE, nuclear extracts
ester-induced suppression of a1(I) collagen mRNA isomitted; Comp, competition study; Estr, estradiol; Cyclo, cyclohexi-
mide. *P , 0.001 vs. Con; **P , 0.001 vs. Con; P , 0.05 vs. Estr 1 reversed by curcumin [32]. However, the suppressive
Cyclo. effects of phorbol esters and of AP-1 on type I collagen
synthesis is cell type specific insofar as these agents have
been shown to stimulate type I collagen synthesis in
other cell types [15].
tains a highly conserved nonconsensus AP-1 binding re- Our data are consistent with the hypothesis that the
gion that is a critical determinant of transcriptional activ- transcription factor AP-1 suppresses type I collagen syn-
ity [8, 16, 17]. This motif acts as a positive element in thesis in cultured murine mesangial cells. Stimulation of
human, rat, and chicken fibroblasts, dedifferentiated hu- AP-1 by short-term exposure to PMA resulted in decreased
man chondrocytes, and rat Ito cells [8, 15–17, 31], and type I collagen synthesis. In contrast, exposure to curcu-
it acts as a negative element in A204 cells [15]. In addi- min, an inhibitor of AP-1, increased collagen synthesis.
tion, a consensus AP-1 binding site is located far up- Corresponding to these effects, we found that nuclear
stream in the a1(I) promoter [13, 14]. This motif acts as extracts from PMA-treated mesangial cells showed in-
a negative transcriptional element in murine myocardial creased binding to a consensus sequence AP-1 binding site.
fibroblasts and osteoblastic cells [13, 14]. Constitutive We also investigated the interrelationship between
expression of c-fos suppresses a1(I) transcription in mu- type I collagen synthesis, AP-1, and estradiol. We found
rine osteoblastic cells by activating this site [13]. that estradiol induced a rapid increase in the steady-
The a2(I) collagen gene promoter also contains an state message for c-fos in cultured mesangial cells, which
AP-1 binding motif [11, 12]. It has been postulated that peaked at 30 minutes and returned to baseline levels by
the relative binding of c-Jun versus Jun B to this motif one hour. Corresponding to the increase in c-fos mRNA,
modulates gene transcription [11, 12]. However, it has nuclear extracts from cells treated with estradiol showed
recently been suggested that AP-1 does not bind to this increased binding to an AP-1 consensus binding sequence
oligonucleotide. The specificity of binding was confirmedsite in vivo [32]. This conclusion was based on the obser-
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Fig. 6. (Top) Effects of the indicated agents
on the binding of nuclear extracts to a consensus
binding sequence AP-1 oligonucleotide (TRE).
Lane 1, control; lane 2, nuclear extracts omit-
ted; lane 3, competition with excess cold AP-1
oligonucleotide; lane 4, estradiol (1027 m, 4
hr); lane 5, estradiol (4 hr) 1 curcumin (1 mm);
lane 6, curcumin (1 mm); lane 7, control; lane 8,
nuclear extracts omitted; lane 9, competition
with excess cold AP-1 oligonucleotide; lane
10, phorbol 12-myristate 13-acetate (PMA; 10
mm); lane 11, PMA 1 curcumin; lane 12, cur-
cumin. (Bottom) Densitometry readings from
gel shift studies measuring the effects of the
indicated agents on the binding of nuclear ex-
tracts to a consensus binding sequence AP-1
oligonucleotide (TRE). Abbreviations are:
Con, control; 2NE, nuclear extracts omitted;
Comp, competition study; Estr, estradiol; Cur,
curcumin; PMA, phorbol 12-myristate 13-ace-
tate. *P , 0.001 vs. Con; **P , 0.001 vs. Con;
P , 0.035 vs. Estr 1 Cur; ***P , 0.02 vs.
Con; P , 0.03 vs. PMA 1 Cur.
by competition studies using excess cold AP-1 oligonu- Several members of the metalloproteinase family of
proteases, tissue inhibitor of metalloproteinase-1, andcleotide and by supershift assays. Estradiol-enhanced
binding was dependent on new protein synthesis because several proteins interacting with the serine proteinase
family contain AP-1 response elements in their promoterit was reversed by cycloheximide. These data suggest
that estradiol reduces type I collagen synthesis by induc- or enhancer regions [47]. To eliminate the possibility
that changes in the amount of collagen I present in theing the expression of AP-1, which in turn binds to AP-1
regulatory motifs on type I collagen genes to suppress cell culture media were due to changes in the rate of
collagen degradation, we measured type I collagen bothtranscription. However, our studies do not identify the
regulatory sites to which AP-1 binds. in the presence and absence of protease inhibitors. Re-
sults were identical whether or not protease inhibitorsThe ratio of the steady-state levels of mRNA for a1(I)
and a2(I) collagen is identical to the ratio of the rates at were present, suggesting that differences in the amount
of collagen I present in the media were due to differenceswhich the two chains are synthesized (2:1) [6, 7]. Because
transcription of the a1(I) and a2(I) collagen genes are under in the rate of synthesis.
In addition to the classic estrogen receptor (ERa), acoordinate control, our data suggest that binding of AP-1
to AP-1 regulatory sites in both the a1(I) and a2(I) colla- second class of estrogen receptors (ERb) has been de-
scribed [48–50]. In cells transfected with a reporter genegen genes are involved in the suppression of type I colla-
gen synthesis after exposure to PMA or estradiol. construct under the transcriptional control of an AP-1–
responsive element, estradiol activated gene transcrip-The reduction in mesangial cell type I collagen synthe-
sis induced by estradiol achieved statistical significance tion in cells cotransfected with ERa but repressed tran-
scription in cells cotransfected with ERb [50]. A role forat an estradiol concentration of 5 3 1029 m. In normal
menstruating women, the serum concentration of estra- ERa in explaining our findings is unlikely because of the
failure to detect ERb in kidney tissue [48, 49]. However,diol in the early follicular phase is 2 3 10210 m and rises
to 1.2 to 2.6 3 1029 m in the late follicular phase [46]. mesangial cells have not specifically been studied.
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